Hartman Jorine E, van der Molen Marieke C, Jonker Marnix R, Posthuma Rein, Vanfleteren Lowie E G W, Slebos Dirk-Jan, Pouwels Simon D
University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, The Netherlands.
University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands.
ERJ Open Res. 2025 Mar 10;11(2). doi: 10.1183/23120541.00665-2024. eCollection 2025 Mar.
Bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) is an effective treatment for severe COPD patients by improving lung function and quality of life. However, little is known about its effects on systemic inflammation. Therefore, the aim of our study was to investigate whether EBV treatment impacts the inflammatory cytokine profile.
This study was a predefined sub-study of the SoLVE trial (NCT03474471) that investigated the combination of EBV treatment with pulmonary rehabilitation (PR). The sub-study included the collection of blood samples with assessment of 10 inflammatory markers prior to EBV treatment and 6 months after EBV or EBV+PR treatment.
In 66 patients, 6 months after treatment a pro-inflammatory cytokine profile was observed, with an increase in all pro-inflammatory markers and a decrease in the anti-inflammatory cytokine interleukin-10. The changes in plasma cytokine profile were not associated with changes in clinical outcomes such as lung function or exercise capacity.
In conclusion, our study demonstrated an elevation in systemic pro-inflammatory cytokine levels following successful EBV treatment, which was not associated with adverse clinical outcomes. It would be interesting to further explore whether this increase is attributed to a foreign body response or if other factors contribute to this phenomenon.
使用支气管内瓣膜（EBV）进行支气管镜肺减容治疗是一种通过改善肺功能和生活质量来治疗重度慢性阻塞性肺疾病（COPD）患者的有效方法。然而，其对全身炎症的影响却知之甚少。因此，我们研究的目的是调查EBV治疗是否会影响炎症细胞因子谱。
本研究是SoLVE试验（NCT03474471）的一项预先定义的子研究，该试验研究了EBV治疗与肺康复（PR）的联合应用。该子研究包括在EBV治疗前以及EBV或EBV + PR治疗后6个月采集血样并评估10种炎症标志物。
在66例患者中，治疗6个月后观察到促炎细胞因子谱，所有促炎标志物均升高，抗炎细胞因子白细胞介素-10降低。血浆细胞因子谱的变化与肺功能或运动能力等临床结果的变化无关。
总之，我们的研究表明，成功进行EBV治疗后全身促炎细胞因子水平升高，这与不良临床结果无关。进一步探究这种升高是否归因于异物反应或是否有其他因素导致这一现象将很有意思。
